论文部分内容阅读
目的:探讨亚砷酸注射液治疗原发性肝癌的临床疗效。方法:将75例中晚期原发性肝癌患者随机分为两组,其中治疗组45例,对照组30例;对照组仅接受单纯中药辨证治疗和一般对症、支持治疗,治疗组在对照组治疗基础上还接受亚砷酸注射液治疗。结果:(1)治疗组获部分缓解(PR)8例,无变化(NC)27例,恶化(PD)10例,有效率[完全缓解(CR)+PR]为17.78%;对照组获PR 4例,NC 14例,PD 12例,有效率为13.33%;经X2检验,两组间客观疗效无显著性差别(P=0.142>0.05)。(2)治疗组在改善肝功能、AFP方面较明显,两组比较有显著性差异,在改善KPS评分方面两组无显著性差别。治疗组未见明显毒副反应发生。(3)治疗组和对照组患者中位生存时间分别为(219±10.22)天、(182±9.37)天,两者差别有统计学意义(P=0.009<0.01)。结论:亚砷酸注射液可延长中晚期肝癌患者的中位生存期,且无明显毒副反应。
Objective: To investigate the clinical efficacy of arsenite injection in the treatment of primary liver cancer. Methods: Seventy-five patients with advanced primary liver cancer were randomly divided into two groups, including 45 cases in the treatment group and 30 cases in the control group. The control group received only TCM syndrome differentiation and general symptomatic treatment and supportive treatment. Based on the treatment of arsenite injection. Results: (1) In the treatment group, there were 8 cases of partial remission (PR), 27 cases of no change (NC) and 10 cases of worsening (PD). The effective rate [complete remission (CR) 4 cases, 14 cases of NC, 12 cases of PD, the effective rate was 13.33%. There was no significant difference between the two groups (P = 0.142> 0.05) by X2 test. (2) The treatment group is more obvious in improving liver function, AFP, the two groups were significantly different, there was no significant difference between the two groups in improving KPS score. The treatment group showed no obvious side effects. (3) The median survival time in the treatment group and the control group were (219 ± 10.22) days and (182 ± 9.37) days, respectively, with a significant difference between the two groups (P = 0.009 <0.01). Conclusion: Arsenite injection can prolong the median survival of patients with advanced liver cancer, and no significant side effects.